Chapter 25 and 28 Flashcards
Coronary Artery Disease
Narrowing or occlusion of a coronary artery
Narrowing causes myocardial ischemia
atherosclerosis
Most common etiology of CAD
Caused by presence of plaque & inflammation
Nitrates
Potent vasodilators (coronary arteries) main treatment for angina
Nitrates action
relax arterial & venous smooth muscle
Reduces preload → decreases cardiac output and cardiac demand → myocardial oxygen demand
Nitrates adverse effects
Headache, dizziness, hypotension, flushing, rash
Avoid with nitrates
no alcohol
no viagra
Myocardial Infarction tx
Nitrates Beta-blockers Thrombolytics Asprin Statins for hyperlipidemia ACE inhibitors Platelet Aggregation Inhibitors Heparin drip
Hematopoiesis
Process of blood-cell formation
Where does hematopoiesis begin
Begins with stem cells in bone marrow
Where is hematopoiesis begin
Homeostatic control maintained by hormones and growth factors
Demands of body on WBC
White blood cells (WBCs) can increase concentration up to ten times normal
Demands of body on RBC
Red blood cells (RBCs) can increase up concentration up to five times normal
Epoetin alfa (Epogen, Procrit) category
Erythropoiesis-stimulating Agents
Epoetin alfa (Epogen, Procrit) action
Hormone that stimulates RBC production
Secreted inreduction in oxygen
Body experiences hypoxia or hemorrhage
Epoetin alfa (Epogen, Procrit) use
anemia due to CRF, HIV infection treated with AZT, some cancers
Epoetin alfa (Epogen, Procrit) adverse effects
Hemoglobin > 12 g/dL increased risk death, arterial & venous thromboembolic events, tumor progression
HTN, H/A, seizures, flu-like symptoms, N/V/D, rash
Black box warning
Darbepoetin alfa (Aranesp) category
Erythropoiesis-stimulating Agents
Darbepoetin alfa (Aranesp) duration
Longer duration of action than Epoetin alfa: administered 1x/week
Darbepoetin alfa (Aranesp) uses
anemia due to CRF & chemotherapy
erythropoiesis-stimulating agents (ESAs) FDA warning
not for use in PT’s w/ cancer or getting myelosuppressive therapy when the anticipated outcome is cure